Optimal duration of oral anticoagulant therapy in venous thromboembolism

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 693-698

  Schulman, Sam ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; SECONDARY PREVENTION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 0030792551     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657614     Document Type: Conference Paper

References (33)

1. Bynum LJ, Wilson JE. Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med 1979; 67: 553-6.
2. Vitoux J-F, Fiessinger J-N, Roncato M, Pernes J-M, Brenot P, Aiach M. Long-term treatment of acute deep venous thrombosis with low-molecular-weight heparin derivative. JAMA 1988; 259: 1180-1.
3. Lehman J. Hypoprothrombinaemia produced by methylene-bis-(hydroxycoumarin), its use in thrombosis. Lancet 1942; 1: 318.
4. Allen EV, Barker NW, Waugh JM. A preparation from spoiled sweet clover (3,3′-methylene-bis-(4-hydroxycoumarin)) which prolongs coagulation and prothrombin time of the blood: a clinical study. JAMA 1942; 120: 1009-15.
5. O'Sullivan EF. Duration of anticoagulant therapy in venous thromboembolism. Med J Aust 1972; 2: 1104-7.
6. Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S. 1 month versus 6 months therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-84.
7. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis - a randomized study. Acta Med Scand 1985; 217: 547-52.
8. Fennerty AG, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PA. A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism. Clin lab Haemat 1987; 9: 17-21.
9. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
10. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson K-Å, Hjorth M, Linder O, Boberg J and The Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
11. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E and The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: in press.
12. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606.
13. Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probability of recurrent thromboembolism and haemorrhage. Am J Med 1986;81:255-9.
14. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 1-7.
15. Sarasin FP, Bounameaux. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemostas 1994;71:286-91.
16. Bounameaux H, de Moerloose P, Sarasin FP. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Blood Coag Fibrinol 1996; 7: 507-14.
17. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical cause of acute deep venous thrombosis. Ann Int Med 1996;125: 1-7.
18. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited Thrombophilia: Part 2. Thromb Haemost 1996: 76: 824-34.
19. Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost 1994; 71: 15-8.
20. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
21. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
22. Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter Ch. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
23. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
24. Zöller C, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
25. van Boven H, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with antithrombin deficiency. Thromb Haemost 1996, in press.
26. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens Ch, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
27. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
28. Korninger C, Lechner K, Niessner H, Goessinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of thrombosis. Thromb Haemost 1984; 52: 127-30.
29. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
30. Schulman S, Wiman B and the Duration of Anticoagulation (DURAC) Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607-11.
31. Elias A, Bonfils S, Daoud-Elias M, Gauthier B, Sié P, Boccalon H, Boneu B. Influence of long-term oral anticoagulants upon prothrombin fragment 1+2, thrombin-antithrombin III complex and D-dimer levels in patients affected by proximal deep vein thrombosis. Thromb Haemost 1993; 69: 302-5.
32. Andrew M, Marzinotto V, Brooker LA, Adams M, Ginsberg J, Freedom R, Williams W. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost 1994; 71: 265-9.
33. David M, Manco-Johnson M, Andrew M. Diagnosis and treatment of venous thromboembolism in children and adolescents. Thromb Haemost 1995; 74: 791-2.